Thus, we conclude that HDAC3 plays a distinct role from HDAC1 and HDAC2 during chromatin maturation (Figure 6) and that targeting HDAC3 with small molecule inhibitors will provide additional therapeutic impact in the treatment of CTCL and other cancers. The gene discussed is HDAC1; the disease is cancer.